Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Scand J Infect Dis ; 39(8): 690-6, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17654345

RESUMO

Rapidly growing mycobacteria (RGM) are ubiquitous in the environment but cause lung disease in only a fraction of exposed individuals. This variable susceptibility to disease implies vulnerability to RGM infection due to weakness in host defense. Since most persons who contract RGM lung disease have no known host defense defect, it is likely that uncharacterized host deficiencies exist that predispose to RGM infection. Alpha-1-antitrypsin (AAT) is a host factor that may protect individuals from respiratory infections. Therefore, we assessed AAT protein anomalies as a risk factor for RGM lung disease. In a cohort of 100 patients with RGM lung disease, Mycobacterium (M.) abscessus was the most prevalent organism, isolated in 64 (64%) subjects. Anomalous AAT proteins were present in 27% of the cohort, which is 1.6 times the estimated prevalence of anomalous AAT proteins in the United States population (p=0.008). In in vitro studies, both AAT and a synthetic inhibitor of serine proteases suppressed M. abscessus infection of monocyte-derived macrophages by up to 65% (p<0.01). AAT may be an anti-RGM host-defense factor, and anomalous AAT phenotypes or AAT deficiency may constitute risk factors for pulmonary disease due to RGM.


Assuntos
Macrófagos/microbiologia , Mycobacteriaceae/patogenicidade , Infecções por Mycobacterium não Tuberculosas/enzimologia , Tuberculose Pulmonar/enzimologia , Deficiência de alfa 1-Antitripsina/genética , alfa 1-Antitripsina/genética , Estudos de Coortes , Feminino , Predisposição Genética para Doença , Humanos , Masculino , Pessoa de Meia-Idade , Mycobacteriaceae/crescimento & desenvolvimento , Fenótipo , Estudos Retrospectivos , Inibidores de Serina Proteinase/farmacologia , alfa 1-Antitripsina/sangue , alfa 1-Antitripsina/farmacologia , Deficiência de alfa 1-Antitripsina/microbiologia
2.
Am J Respir Crit Care Med ; 169(5): 604-9, 2004 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-14656754

RESUMO

The concentration and size distribution of infectious aerosols produced by patients with pulmonary tuberculosis (TB) has never been directly measured. We aimed to assess the feasibility of a method that we developed to collect and quantify culturable cough-generated aerosols of Mycobacterium tuberculosis. Subjects were recruited from a referral hospital and most had multidrug-resistant TB. They coughed into a chamber containing microbial air samplers while cough frequency was measured during two 5-minute sessions. Cough-generated aerosol cultures were positive in 4 of 16 subjects (25%) with smear-positive pulmonary TB. There was a rapid decrease in the cough-generated aerosol cultures within the first 3 weeks of effective treatment. Culture-positive cough aerosols were associated with lack of treatment during the previous week (p = 0.007), and there was a trend in the association with cough frequency (p = 0.08). The size distributions of these aerosols were variable, but most particle sizes were in the respirable range. Quantification of viable cough-generated aerosols is feasible and offers a new approach to study infectiousness and transmission of M. tuberculosis and other airborne pathogens.


Assuntos
Microbiologia do Ar , Tosse/microbiologia , Monitoramento Ambiental/métodos , Mycobacterium tuberculosis , Escarro/microbiologia , Tuberculose Resistente a Múltiplos Medicamentos/transmissão , Tuberculose Pulmonar/transmissão , Aerossóis , Impressões Digitais de DNA , DNA Bacteriano/análise , DNA Bacteriano/genética , Monitoramento Ambiental/normas , Monitoramento Epidemiológico , Estudos de Viabilidade , Feminino , Humanos , Masculino , Epidemiologia Molecular , Mycobacterium tuberculosis/genética , Mycobacterium tuberculosis/isolamento & purificação , Mycobacterium tuberculosis/patogenicidade , Tamanho da Partícula , Reprodutibilidade dos Testes , Viés de Seleção , Sensibilidade e Especificidade , Tuberculose Resistente a Múltiplos Medicamentos/complicações , Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico , Tuberculose Resistente a Múltiplos Medicamentos/epidemiologia , Tuberculose Resistente a Múltiplos Medicamentos/microbiologia , Tuberculose Pulmonar/complicações , Tuberculose Pulmonar/tratamento farmacológico , Tuberculose Pulmonar/epidemiologia , Tuberculose Pulmonar/microbiologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa